By using this website, you agree to the terms of this privacy statement.
When you apply for or request specific Smith & Nephew services (such as subscriptions to email and newsletters) we will collect personal identifiable information related to the purpose and use of that service, which we will use to provide the services requested. This site is not intended for children under the age of 18. We will not knowingly collect personally identifiable information from visitors to this site who are less than 18 years old. We encourage parents to talk with their children about the use of the internet and the information they disclose to websites.
We will never disclose your personal identifiable information to third parties for the purposes of allowing them to market to you.
Smith & Nephew operates globally, and this means we may transfer your personal identifiable information to other countries whose privacy laws may be different from those in the U.S. If you do not want your personal identifiable information transferred in this manner, please do not provide it to us on the website.
As you navigate through this website we will collect anonymous information about you and your activities during your visit. This is collected automatically. This information includes navigational data and web server logs, and may include (but is not limited to) information such as your IP address, the version of both your browser and operating system, and the URL of the website you just came from.
A cookie is a small file of letters and numbers that we store on your browser or the hard drive of your computer if you agree. Cookies contain information that is transferred to your computer's hard drive.
The cookies we use are either "analytical" cookies, or “session” cookies. Analytical cookies allow us to recognise and count the number of visitors and to see how you and other visitors move around the website. This helps us to improve the way our website works, for example, by ensuring that users are finding what they are looking for easily. Session cookies allow us to remember you if you have been asked to log in to all or part of our website.
Smith & Nephew PLC, registered office 15 Adam St, London, United Kingdom, WC2N 6LA, is a holding company and is not an operating company. Therefore, products and services are provided exclusively by subsidiaries and not by Smith & Nephew PLC. "Smith & Nephew" may refer to Smith & Nephew PLC itself or one or more of its subsidiaries.
With the exception of websites under our control, if this website is linked to/from other websites, or if other websites are linked to/from this website, Smith & Nephew does not endorse or have any responsibility for the content of such other websites, and Smith & Nephew shall not be liable for any damages or injury arising from the content (or the use of your data) of any other website.
This privacy statement is subject to change, and Smith & Nephew will not proactively notify you of any such changes. It is your responsibility to ensure you visit this web page regularly to review any changes that may have been made since your previous visit.
This agreement shall be governed by the laws of the state of Tennessee and any disputes subject to the exclusive jurisdiction of the courts of the United States of America.
This statement was last updated on 15 May 2012.
Copyright © 2015 Smith & Nephew
IMPORTANT SAFETY INFORMATION
WARNING: INCREASED RATE OF MORTALITY SECONDARY TO MALIGNANCY
An increased rate of mortality secondary to malignancy was observed in patients treated with 3 or more tubes of REGRANEX® Gel in a postmarketing retrospective cohort study. REGRANEX® Gel should only be used when the benefits can be expected to outweigh the risks. REGRANEX® Gel should be used with caution in patients with known malignancy.
Indication and limitations of useREGRANEX® (becaplermin) Gel is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. REGRANEX® Gel is indicated as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control.
- The efficacy of REGRANEX® Gel has not been established for the treatment of pressure ulcers and venous stasis ulcers and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue (Stage I or II, IAET staging classification) or ischemic diabetic ulcers.
- The effects of REGRANEX® Gel on exposed joints, tendons, ligaments, and bone have not been established in humans.
- REGRANEX® Gel is a non-sterile, low bioburden preserved product. Therefore, it should not be used in wounds that close by primary intention.
ContraindicationsREGRANEX® Gel is contraindicated in patients with known neoplasm(s) at the site(s) of application. REGRANEX® Gel is contraindicated in patients with known hypersensitivity to any component of the product (e.g., parabens).
Warnings and precautionsMalignancies distant from the site of application have been reported in both a clinical study and in postmarketing use. REGRANEX® Gel should be used with caution in patients with a known malignancy.
If application site reactions occur, the possibility of sensitization or irritation caused by parabens or m-cresol should be considered.
Commonly observed adverse reactionsIn clinical trials, erythematous rashes occurred in 2% of patients treated with REGRANEX® Gel (and good ulcer care) or placebo (and good ulcer care), and none in patients receiving good ulcer care alone.
See warnings above regarding malignancy.
Burning sensation at the site of application and erythema have been reported during post-approval use of REGRANEX® Gel.
Other important informationThe amount of REGRANEX® Gel to be applied should be recalculated by the physician or wound caregiver at weekly or biweekly intervals depending upon the rate of change in ulcer area.
If the ulcer does not decrease in size by approximately 30% after 10 weeks of treatment or complete healing has not occurred in 20 weeks, continued treatment with REGRANEX® Gel should be reassessed.
Pregnancy & Nursing Mothers: Pregnancy Category C. REGRANEX® Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether becaplermin is excreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when REGRANEX® Gel is administered to nursing women.
Safety and effectiveness of REGRANEX® Gel in pediatric patients below the age of 16 years have not been established.
Counsel patients to review the Medication Guide and to discuss any questions or concerns with their healthcare provider before starting REGRANEX® Gel and at regular intervals during treatment, including when their prescription is refilled.
To report suspected adverse reactions, contact Smith & Nephew at 1-800-441-8227 or contact FDA at www.fda.gov/medwatch or at 1-800-FDA-1088.
Please see accompanying full Prescribing Information and Medication Guide.